

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY. THIS IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES.



(Please scan this QR code to view Red Herring Prospectus and Abridged Prospectus)

ABH HEALTHCARE LIMITED

(TO BE LISTED ON EMERGE PLATFORM OF NATIONAL STOCK EXCHANGE OF INDIA LIMITED ('NSE EMERGE'))

Our Company was originally incorporated as a private limited company in the name and style of "ABH Healthcare Private Limited" under the Companies Act, 2013 vide certificate of incorporation dated March 2, 2021 issued by Registrar of Companies, Central Registration Centre. Further, in accordance with the main objects, our Company acquired the sole proprietorship concern of Dr. Kamal Baghi, our Promoter in the name "Anil Baghi Hospital" pursuant to a Business Transfer Agreement dated March 16, 2022. Subsequently, our Company was converted from a private limited company to a public limited company, pursuant to a resolution passed in the Extraordinary general meeting of our members held on October 7, 2024 and consequently, the name of our Company was changed to "ABH Healthcare Limited", and a fresh certificate of incorporation consequent upon conversion dated November 15, 2024 was issued by the Registrar of Companies, Chandigarh.

For details of changes in name and the registered office of the Company, see "History and Certain Corporate Matters - Changes in the Registered Office" on page 154 of the Red Herring Prospectus dated August 13, 2026 ("RHP" or "Red Herring Prospectus").

Registered Office: Anil Baghi Road, Ferozepur, Punjab - 152002, India. Contact Person: Mr. Rahul Sharma, Company Secretary & Compliance Officer, Mob No: +91 7888690116; Email: investor@anilbaghihospital.com; Website: www.abhhealthcare.org; Corporate Identity Number: U85300PB2021PLC052886

THE PROMOTERS OF OUR COMPANY ARE: DR. KAMAL BAGHI, DR. SAURABH BAGHI AND DR. VAISHALI SAINI

THE ISSUE

INITIAL PUBLIC ISSUE* OF UPTO 34,29,600 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH ("EQUITY SHARES") OF ABH HEALTHCARE LIMITED, ("ABH" OR THE "OUR COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹[•]/- PER EQUITY SHARE (INCLUDING A SECURITIES PREMIUM OF ₹[•]/- PER EQUITY SHARE) (THE "ISSUE PRICE") AGGREGATING TO ₹[•] LAKHS (THE "ISSUE"), OF WHICH 1,72,800* EQUITY SHARES OF FACE VALUE OF ₹10/- EACH FOR CASH AT A PRICE OF ₹[•]/- PER EQUITY SHARE INCLUDING A SECURITIES PREMIUM OF ₹[•]/- PER EQUITY SHARE AGGREGATING TO ₹[•] LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. NET ISSUE OF 32,56,800 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH AT A PRICE OF ₹[•]/- PER EQUITY SHARE INCLUDING A SECURITIES PREMIUM OF ₹[•]/- PER EQUITY SHARE AGGREGATING TO ₹[•] LAKHS IS HEREINAFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 30.01% AND 28.49%, RESPECTIVELY, OF THE POST-ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY. FOR FURTHER DETAILS, PLEASE REFER THE CHAPTER TITLED "TERMS OF THE ISSUE" ON PAGE 259 OF THE RHP.

*Subject to finalization of basis of allotment

DETAILS OF THE SELLING SHAREHOLDERS, OFFER FOR SALE AND WEIGHTED AVERAGE COST OF ACQUISITION: Not applicable as the entire issue constitutes fresh issue of equity shares.

PRICE BAND: ₹ 96 TO ₹ 102 PER EQUITY SHARE OF FACE VALUE OF ₹ 10/- EACH

THE FLOOR PRICE IS 9.60 TIMES THE FACE VALUE OF THE EQUITY SHARES AND THE CAP PRICE IS 10.20 TIMES THE FACE VALUE OF THE EQUITY SHARES

THE PRICE TO EARNING RATIO BASED ON DILUTED EPS FOR FY 2026 AT THE FLOOR PRICE IS 13.62 TIMES AND AT THE CAP PRICE IS 14.47 TIMES.

BIDS CAN BE MADE FOR A MINIMUM OF 1,200 EQUITY SHARES AND IN MULTIPLES OF 2,400 EQUITY SHARES THEREAFTER.

WEIGHTED AVERAGE RETURN ON NET WORTH FOR THE LAST THREE FISCAL YEARS SHOULD BE READ AS 44.51%

The details of the Fresh Issue and the Post-Issue Market Capitalisation of the Company, each at the Floor Price (₹ 96) and the Cap Price (₹ 102), are given below

Particulars	At Floor price of ₹ 96 per equity share		At Cap price of ₹ 102 per equity share	
	Upto No. of equity shares of face value of Rs.10/- each	Upto amount (Rs in lakhs)	Upto No. of equity shares of face value of Rs.10/- each	Upto amount (Rs in lakhs)
Fresh Issue	34,29,600	3,292.42	34,29,600	3,498.19
Offer for Sale	-	-	-	-
Total Issue Size	34,29,600	3,292.42	34,29,600	3,498.19
Post-Issue Market Capitalization of the Company	1,14,29,600	10,972.42	1,14,29,600	11,658.19

BID/ISSUE PROGRAMME*

BID/ISSUE OPENS ON: MONDAY AUGUST 24, 2026

BID/ISSUE CLOSSES ON: WEDNESDAY AUGUST 26, 2026 ^{(1) (2)}

*Our Company in consultation with the BRLM has decided that no participation by anchor investors will be considered in the IPO.

(1) Our Company, in consultation with the BRLM, may consider closing the Bid/Issue Period for QIBs one Working Day prior to the Bid/Issue Closing Date, in accordance with the SEBI ICDR Regulation.

(2) The UPI mandate end time and date shall be at 5:00 p.m. on the Bid/Issue Closing Day.

BRIEF DESCRIPTION OF THE BUSINESS OF THE COMPANY

Our core focus is on providing specialised tertiary medical care in Tier 3 cities, within the state of Punjab while seeking to strike a balance between providing quality healthcare services and affordability. We operate our hospital under the "Anil Baghi Hospital" brand, honoring the sacrifice of late Shri Anil Baghi. Located in Ferozepur, Punjab, our hospital has a capacity of 150 beds.

Acquired by our Company in 2022, the hospital was established in 1985 with 30 (thirty) beds and is driven by a vision to provide affordable, accessible, and quality healthcare services, delivered with compassion. Since our acquisition, we have consistently invested in the hospital, expanding bed capacity, increasing our workforce, and introducing additional services and clinical specialties.

THE ISSUE IS BEING THROUGH BOOK BUILDING PROCESS IN ACCORDANCE WITH CHAPTER IX (INITIAL PUBLIC OFFER BY SMALL AND MEDIUM ENTERPRISES) OF THE SEBI (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED FROM TIME TO TIME ("SEBI ICDR REGULATIONS")

THE EQUITY SHARES OF THE COMPANY WILL GET LISTED ON EMERGE PLATFORM OF NATIONAL STOCK EXCHANGE OF INDIA LIMITED ('NSE EMERGE')

DETAILS OF ALLOCATION

• QIB CATEGORY: NOT MORE THAN 9.00% OF THE NET ISSUE

• INDIVIDUAL INVESTOR CATEGORY : NOT LESS THAN 45.50% OF THE NET ISSUE

• NON INSTITUTIONAL INVESTOR CATEGORY: NOT LESS THAN 45.50% OF THE NET ISSUE

• MARKET MAKER RESERVATION PORTION: UPTO 1,72,800 EQUITY SHARES OR 5.04% OF THE ISSUE

IN MAKING AN INVESTMENT DECISION, POTENTIAL INVESTORS MUST ONLY RELY ON THE INFORMATION INCLUDED IN THE RHP AND THE TERMS OF THE ISSUE, INCLUDING THE RISKS INVOLVED AND NOT RELY ON ANY OTHER EXTERNAL SOURCES OF INFORMATION ABOUT THE OFFER AVAILABLE IN ANY MANNER

In accordance with the recommendation of the Independent Directors of our Company, pursuant to their resolution dated August 13, 2026 the above provided price band is justified based on quantitative factors/ KPIs disclosed in the Section "Basis for Issue Price" on page 97 of the RHP vis-a-vis the weighted average cost of acquisition ("WACA") of primary and secondary transaction(s), as applicable, disclosed in the section titled "Basis for Issue Price" on page 97 of the RHP and provided below in this advertisement.

RISKS TO INVESTORS

For details refer to section titled "Risk Factors" on page no. 29 of RHP

1. Risk to investors: Summary description of key risk factors based on materiality.

- Our Company has been specifically formed for the purpose of acquisition of the business of M/s. Anil Baghi Hospital (sole proprietorship concern of one of our Promoters), thus we have limited operating history as a Company which may make it difficult for investors to evaluate our historical performance or future prospects.
- Our revenues are significantly dependent on our only hospital in Ferozepur, Punjab, any change in the economic or political circumstances in or around the areas of Ferozepur, could materially affect our business, financial condition and results of operations.
- If we are unable to keep pace with technological changes, new equipments and service introductions, changes in patients' needs and evolving industry standards as well as failure or malfunction of our medical or other equipments, our business and financial condition may be adversely affected.
- We rely on certain third parties, including suppliers, and also enter into contracts with third-party payers such as insurance companies, third party administrators, corporations and government departments. Termination, non-renewal or any breach of the conditions of such contracts could have a material adverse impact on our business, financial condition and results of operations.
- We operate in a highly regulated industry, and compliance with applicable safety, health, environmental and other governmental regulations and any violations of existing regulations may adversely affect our business, results of operations and cash flows.
- Our Company has acquired M/s. Anil Baghi Hospital, the sole proprietorship concern of one of our Promoters after its incorporation vide Business Transfer Agreement dated March 16, 2022. Any future acquisition of other businesses could result in operating difficulties, integration issues and other adverse consequences due to our limited past experience in businesses.
- We are significantly dependent on our key personnel, including our Promoters, Dr. Kamal Baghi, Dr. Saurabh Baghi, Dr. Vaishali Saini, senior management and other healthcare professionals and any loss of or our inability to attract or retain such persons could adversely affect our business, financial condition, results of operations and cash flows.
- The object of making unidentified acquisitions may lead to significant investments in the businesses that may not be sustainable in the long run, which may result in financial losses and negatively impact the company's overall portfolio.
- We do not own the premises where our Registered office and hospital are located. Any adverse event that requires us to vacate the said property may materially adversely affect our business operations and financial conditions
- We have a high debt-equity ratio and may face certain funding risks. Any further increase in borrowings may have a material adverse effect on our business, financial condition and results of operations. Further, if we do not generate sufficient amount of cash flow from operations, our liquidity and ability to service our indebtedness could be adversely affected.

2. Details of suitable ratios of the company for the latest full financial year

Name of the Company	CMP	Face Value (₹)	Revenue from Operations (₹ in Lakhs)	EBITDA	Return On Equity	Return On Capital Employed	EPS (Basic) (₹)	EPS (Diluted) (₹)	P/E*	Return on Net Worth (%)	Net Worth (₹ in Lakhs)	Net Asset Value Per Equity Share (₹)
ABH Healthcare Limited	[•]	10	5,250.69	1,471.65	39.07	19.09	7.05	7.05	[•]	34.26	1,726.54	21.58
Listed Peers*												
Sangani Hospitals Limited	53.20	10	10,695.81	808.63	16.20	20.27	2.17	2.17	24.52	16.20	3,210.65	23.30
Maitreya Medicare Limited	124.15	10	4,484.99	(45.22)	(8.10)	(4.43)	(3.64)	(3.64)	(34.11)	(8.10)	2,891.49	42.67
Asari Hospital Limited	234	10	17,350.29	3,527.76	18.65	16.67	8.47	8.47	27.63	18.65	9,764.41	49.62

Notes:

- Revenue from Operations means the Revenue from Operations as appearing in the Restated Consolidated Financial Statements.
- EBITDA is calculated as Restated Profit before tax + Depreciation & amortisation + Interest Expense - Other Income.
- Return on Equity (%) refers to restated profit for the year/period attributable to equity shareholders of our Company divided by Shareholder Equity.
- Return on Capital Employed is calculated as earnings before interest and taxes divided by Capital Employed.
- Basic and Diluted EPS = Net Profit (Loss) after tax as restated attributable to Equity Shareholders / weighted average no. of equity shares outstanding during the year (Post effect of bonus) /period as per Restated Financial Statement
- Return on Net Worth (%) = Net Profit (Loss) after tax as restated attributable to Equity Shareholders / Net worth as restated as at year/period end.
- P/E Ratio for the peer has been computed based on the closing market price of respective equity shares as on August 13, 2026 sourced from website of Stock Exchange as divided by the Basic/diluted EPS as applicable
- RoNW is computed as net profit after tax, as attributable to the owners of the Company divided by closing net worth. Net worth has been computed as the aggregate of share capital and reserves and surplus (excluding Revaluation Reserves) and as attributable to the owners of the Company
- Net worth is aggregate value of the paid-up equity share capital of the Company and all reserves created out of the profits, securities premium account and debit or credit balance of profit and loss account, excluding revaluation reserves if an and share application money, as per Restated Consolidated Financial Statements.
- Net Asset Value per Equity Share is calculated as net worth attributable to equity shareholders as at the end of Financial period/year divided by the weighted average number of closing outstanding Equity Shares
- The figures of ABH Healthcare Limited are based on the Restated Consolidated Financial Statements for the Financial year ended March 31, 2026.
- The figures for the peer group are for the year ended March 31, 2026 and are based on their consolidated financial statements filed with Stock Exchange.

3. Weighted average return on net worth for the last 3 Fys.

Particulars	RoNW (%)	Weights
March 31, 2024	30.33	1
March 31, 2025	59.75	2
March 31, 2026	39.07	3
Weighted Average	44.51	

Note: Return on Net worth has been calculated as per the following formula:

- Return on Net Worth (%) = Net Profit (Loss) after tax as restated attributable to Equity Shareholders / Average Net worth as restated as at year/period end.
- Weighted average = Aggregate of year-wise weighted RoNW divided by the aggregate of weights i.e. (RoNW x Weight) for each year/Total of weights.
- Net worth means the aggregate value of the paid-up equity share capital, share premium account, and reserves and surplus (excluding revaluation reserve) as reduced by the aggregate of intangible assets, miscellaneous expenditure (to the extent not adjusted or written off) and the debit balance of the profit and loss account as per Restated Consolidated Financial Statements.

4. Weighted average cost of acquisition of all equity shares transacted in the preceeding (3) Years, 18 (eighteen) Months and 1 (one) Year preceding the date of the RHP.

Period	Weighted average cost of acquisition* ^	Issue price (₹ [•]) is 'x' times the weighted average cost of acquisition**	Range of acquisition price: Lowest price -Highest price (in ₹)** ^
Last three (3) years	Negligible	N.A.	Nil-33
Last eighteen (18) months	N.A.	N.A.	N.A.
Last one (1) year	N.A.	N.A.	N.A.

* As certified by our Statutory Auditor M/s G D Singhal & Associates, Chartered Accountants, pursuant to their certificate dated August 14, 2026

** The face value of Equity Shares is ₹10/- each

6. Disclosures as per clause (9)(K)(4) of Part A to Schedule VI

a) The price per share of our Company (as adjusted for corporate actions, including split, bonus issuances) based on the primary/ new issue of Equity Shares or convertible securities (excluding Equity Shares issued under the ESOP Scheme and issuance of Equity Shares pursuant to a bonus issue) during the 18 months preceding the date of the RHP, where such issuance is equal to or more than 5% of the fully diluted paid up share capital of our Company in a single transaction or multiple transactions combined together over a span of rolling 30 days ("Primary Transactions")

Except bonus issue of Equity Shares, there has been no issuance of Equity Shares or convertible securities, excluding issuance of bonus shares, during the 18 months preceding the date of the RHP, where such issuance is equal to or more than 5% of the fully diluted paid-up share capital of the Company (calculated based on the Pre-Issue capital before such transaction(s) and excluding ESOPs granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days.

b) Secondary sales / acquisitions of Equity Shares or any convertible securities, where the Promoters, members of the Promoter Group or Shareholder(s) having the right to nominate director(s) on our Board are a party to the transaction (excluding gifts), during the 18 months preceding the date of the RHP, where either acquisition or sale is equal to or more than 5% of the paid up share capital of our Company (calculated based on the pre-Issue capital before such transaction(s)), in a single transaction or multiple transactions combined together over a span of rolling 30 days ("Secondary Transactions").

There have been no secondary sales / acquisitions of Equity Shares, other than gift or any convertible securities, where the Promoters, members of the Promoter Group or Shareholder(s) having the right to nominate director(s) on our Board are a party to the transaction (excluding gifts), during the 18 months preceding the date of the RHP, where either acquisition or sale is equal to or more than 5% of the paid up share capital of our Company (calculated based on the pre-Issue capital before such transaction(s)), in a single transaction or multiple transactions combined together over a span of rolling 30 days ("Secondary Transactions").

c) Since there are no eligible transaction of our Company reported in 8 (a) and 8 (b) above in accordance with paragraph (9)(K)(4)(a) of the SEBI ICDR Regulations, the price per Equity Share of our Company based on the last five primary or secondary transactions in Equity Shares (secondary transactions where the Promoter/ Promoter Group entities or Shareholders having the right to nominate director on the Board are a party to the transaction) not older than 3 years prior to the date of filing of the RHP has been computed as under:

Date of Transfer	Name of Transferee	Name of Transferee	No. Equity Shares Allotted / Transferred	Face value per Equity Share (₹)	Price per Per Equity Shares (₹)	Nature of transaction	Nature of consideration	Total consideration (in ₹) (B)
Primary Issuances								
April 29, 2025	N.A.	Dr. Saurabh Baghi	41,10,000	10	NA	Bonus Issue	Other than Cash	N.A.
April 29, 2025	N.A.	Dr. Kamal Baghi	17,99,988	10	NA	Bonus Issue	Other than Cash	N.A.
April 29, 2025	N.A.	Dr. Vaishali Saini	90,000	10	NA	Bonus Issue	Other than Cash	N.A.
April 29, 2025	N.A.	Mr. Hem Raj Saini	3	10	NA	Bonus Issue	Other than Cash	N.A.
April 29, 2025	N.A.	Mrs. Rita Saini	3	10	NA	Bonus Issue	Other than Cash	N.A.
April 29, 2025	N.A.	Mrs. Sukarna Khanna	3	10	NA	Bonus Issue	Other than Cash	N.A.
Total			59,99,997					N.A.

Weighted Average Cost of Acquisition (primary transactions)

Secondary Issuances

Date of Transfer	Name of Transferee	Name of Transferee	No. Equity Shares Allotted / Transferred	Face value per Equity Share (₹)	Price per Equity Shares (₹)	Nature of transaction	Total consideration (₹)
March 31, 2024	Dr. Kamal Baghi	Dr. Saurabh Baghi	13,20,000	10	Nil	Transfer of Equity Shares by way of gift	N.A.
October 1, 2024	Dr. Kamal Baghi	Mr. Hem Raj Saini	1	10	33	Transfer of Equity Shares	33.00
October 1, 2024	Dr. Kamal Baghi	Mrs. Rita Saini	1	10	33	Transfer of Equity Shares	33.00
October 1, 2024	Dr. Kamal Baghi	Mrs. Sukarna Khanna	1	10	33	Transfer of Equity Shares	33.00
Total			13,20,003				99.00
Weighted Average Cost of Acquisition (secondary transactions)							Negligible

a. Weighted average cost of acquisition and Issue Price:

Type of Transactions	Weighted average cost of acquisition (₹ per Equity Shares)	Floor Price (i.e. ₹ 96)	Cap Price (i.e. ₹ 102)
I. Weighted average cost of acquisition for last 18 months for primary / new issue of shares (equity / convertible securities), excluding shares issued under an employee stock option plan / employee stock option scheme and issuance of bonus shares, during the 18 (eighteen) months preceding the date of filing of the RHP, where such issuance is equal to or more than 5% of the fully diluted paid-up share capital of the Company (calculated based on the pre-issue capital before such transaction/s and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days.	N.A.	N.A.	N.A.
II. Weighted average cost of acquisition for last 18 (eighteen) months for secondary sale/acquisition of shares equity/convertible securities, where promoter/ promoter group entities or shareholder(s) having the right to nominate director(s) in the Board area party to the transaction, during the 18 months preceding the date of filing of the RHP, where either acquisition or sale is equal to or more than five percent of the fully diluted paid-up share capital of the Company (calculated based on the pre-issue capital before such transaction/s and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days	N.A.	N.A.	N.A.
III. Since there are no such transactions to report to under (i) and (ii) above, the information has been disclosed for price per share of our Company based on the last five primary or secondary transactions where our Promoter/members of our Promoter Group or Shareholder(s) having the right to nominate director(s) on the Board of our Company, are a party to the transaction, during the three years prior to the date of filing of the RHP irrespective of the size of the transaction, is as below.	N.A.	N.A.	N.A.
Type of transactions	WACA (in ₹)	Floor Price (in ₹)	Cap Price (in ₹)
a) WACA of Equity Shares based on primary issuances undertaken during the three immediately preceding years.	N.A.	N.A.	N.A.
b) WACA of Equity Shares based on secondary transactions undertaken during the three immediately preceding years.	Negligible	N.A.	N.A.

ADDITIONAL INFORMATION FOR INVESTORS:

1. Details of proposed /undertaken pre-issue placements from the DRHP filing date.

Our Company has not undertaken any pre-Issue placements or Pre-IPO Placements from the date of the filing of the DRHP till the date of filing of the RHP.

2. Transaction of shares aggregating up to 1% or more of the paid-up equity share capital of the company by promoter(s) and promoter group(s) from the DRHP filing date.- Not Applicable

3. Shareholding of Promoter / Promoter Group and Additional Top 10 Shareholders of the Company

S. No.	Pre-Issue shareholding as at the date of Advertisement			Post-Issue shareholding as at Allotment			
	Name of Shareholders	Number of Equity Shares ^(a)	Shareholding(%)	At the Lower end of the Price Band (₹ 96)		At the Upper end of the Price Band (₹ 102)	
				Number of Equity Shares ^(b)	Shareholding(%)	Number of Equity Shares ^(c)	Shareholding(%)
Promoters (A)							
1.	Dr. Saurabh Baghi	54,80,000	68.50	54,80,000	47.95%	54,80,000	47.95%
2.	Dr. Kamal Baghi	23,99,984	30.00	23,99,984	21.00%	23,99,984	21.00%
3.	Dr. Vaishali Saini	1,20,000	1.50	1,20,000	1.05%	1,20,000	1.05%
	Total (A)	79,99,984	100.00	79,99,984	69.99%	79,99,984	69.99%
Promoter Group (B)(1)							
1.	Mr. Hem Raj Saini	4	Nominal	4	Nominal	4	Nominal
2.	Mrs. Rita Saini	4	Nominal	4	Nominal	4	Nominal
3.	Mrs. Sukarna Khanna	4	Nominal	4	Nominal	4	Nominal
	Total (B)	12	Nominal	12	Nominal	12	Nominal
Top 10 Shareholders (other than A & B above)							
1.	Mr. Pradeep Khanna ^	4	Nominal	4	Nominal	4	Nominal
	Total (C)	4	Nominal	4	Nominal	4	Nominal
Other Shareholders (other than A, B & C above)							
N/A							
	Total (D)	N/A	N/A	N/A	N/A	N/A	N/A
Grand Total (A+B+C+D)		80,00,000	100.00	80,00,000	69.99%	80,00,000	69.99%

^ Mr. Pradeep Khanna is the spouse of Mrs. Sukarna Khanna, a member of the Promoter Group.

Notes:

(1) Includes all transfers of Equity Shares by existing shareholders after the date of the pre-Issue and price band advertisement. The Promoter Group shareholders are Mr. Hem Raj Saini, Mrs. Rita Saini and Mrs. Sukarna Khanna

(2) Based on the Issue price of ₹ [•] and subject to finalization of the basis of allotment.

(3) Assuming full subscription in the Issue. The post-issue shareholding details as at allotment will be based on the actual subscription and the final Issue price and updated in the prospectus, subject to finalization of the basis of allotment. Also, this table assumes there is no transfer of shares by these shareholders between the date of the advertisement and allotment. (If any such transfers occur prior to the date of prospectus, it will be updated in the shareholding pattern in the prospectus.

Continued on next page..